文献速递MDS 与骨髓增殖性肿瘤白血病

突变TET2对克隆性及亚克隆层级的影响

Consequences of mutant TET2 on clonality and subclonal hierarchy.
PubMed 文献 · Leukemia · 2018-05-24

该研究在4930例患者中检出1205例携带TET2突变,其中40%为双等位基因突变;超过40%的TET2突变病例中该突变为祖克隆事件,占MDS的8%;克隆层级中TET2病变排名越早(克隆负荷越大)生存越差;由祖克隆TET2突变驱动的MDS可能源自TET2突变克隆性造血,外显率约1%,后续二次打击决定疾病表型。

要点

  • 4930例患者中1205例检出TET2突变,40%的突变病例为双等位基因突变。
  • 超过40%的TET2突变病例中TET2突变为祖克隆事件,占MDS的8%。
  • 克隆层级中TET2病变排名越高(越早、克隆负荷越大)生存越差。

核心结论

  • TET2突变克隆性造血来源的MDS是区别于原发MDS的一个MDS亚类。
  • 祖克隆TET2突变驱动的MDS可能源自TET2突变克隆性造血,外显率约1%。
  • 祖克隆TET2突变之后,个体病程由二次打击决定,二次打击诱导表型向发育异常、骨髓增殖或进展为AML偏移。

研究设计与样本

  • 在不同类型TET2突变肿瘤中,按克隆层级内TET2打击的层次检查表型。
  • 采用深度测序,在4930例患者中检出1205例携带突变,共1781个突变。

主要发现

  • 4930例患者中1205例检出突变,共1781个突变;40%的突变病例为双等位基因突变。
  • 超过40%的TET2突变病例中TET2突变为祖克隆事件,例如占MDS的8%。
  • 克隆层级中TET2病变排名越高(越早、克隆负荷越大)与生存受损相关。
  • 祖克隆TET2突变驱动的MDS可能源自TET2突变克隆性造血,外显率约1%。
  • 多维分析显示,TET2创始缺陷之后的打击诱导表型向发育异常、骨髓增殖或进展为AML偏移。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Somatic mutations in TET2 are common in myelodysplastic syndromes (MDS), myeloproliferative, and overlap syndromes. TET2 mutant (TET2MT) clones are also found in asymptomatic elderly individuals, a condition referred to as clonal hematopoiesis of indeterminate potential (CHIP). In various entities of TET2MT neoplasia, we examined the phenotype in relation to the strata of TET2 hits within the clonal hierarchy. Using deep sequencing, 1781 mutations were found in 1205 of 4930 patients; 40% of mutant cases were biallelic. Hierarchical analysis revealed that of TET2MT cases >40% were ancestral, e.g., representing 8% of MDS. Higher (earlier) TET2 lesion rank within the clonal hierarchy (greater clonal burden) was associated with impaired survival. Moreover, MDS driven by ancestral TET2MT is likely derived from TET2MT CHIP with a penetrance of ~1%. Following ancestral TET2 mutations, individual disease course is determined by secondary hits. Using multidimensional analyses, we demonstrate how hits following the TET2 founder defect induces phenotypic shifts toward dysplasia, myeloproliferation, or progression to AML. In summary, TET2MT CHIP-derived MDS is a subclass of MDS that is distinct from de novo disease.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Hirsch CM, Nazha A, Kneen K, et al. Consequences of mutant TET2 on clonality and subclonal hierarchy. Leukemia. 2018. PMID: 29795413. doi:10.1038/s41375-018-0150-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。